Voiant is the industry leading AI-based clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. Voiant combines leadership in artificial intelligence and visionary computing, key opinion leaders for strategic therapeutic areas alignment, and clinical research experts to deliver operational excellence and consistent execution – providing the shortest path to the highest quality imaging data for clinical trials. Voiant has interpreted +1 billion images from over 700 global clinical trials, aiding numerous biopharmaceutical companies bringing new treatments to patients across oncology, respiratory, ophthalmology, cardiovascular, gastrointestinal, and liver disease domains. Voiant Hub is our built for purpose AI-powered platform, enabling us to manage the entire clinical imaging process while providing site management, as well as full transparency to sponsors every step of the way from image upload, quality control, read & analysis to delivering high quality clinical imaging endpoints.
Viz.AI
Viz.ai is the leading platform, leveraging artificial intelligence and machine learning to improve clinical care and accelerate treatments and technology. The Viz Platform is a transformative solution that uses artificial intelligence to unify synchronized care collaboration, high fidelity mobile image viewing, real-time patient information and secure communication to optimize workflows for better patient care coordination. Viz.ai’s comprehensive vascular portfolio includes care coordination products for detection of suspected pulmonary embolism with automated RV/LV ratio and aortic disease. These solutions leverage advanced deep learning to communicate time-sensitive information about patients straight to a specialist who can intervene and treat. Viz is the most comprehensive and effective AI platform that is already helping to coordinate care across a broad list of clinical applications in more than 1,800 hospitals. | Viz.ai is the leading platform, leveraging artificial intelligence and machine learning to improve clinical care and accelerate treatments and technology. The Viz Platform is a transformative solution that uses AI to unify care collaboration. | Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,800+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.
VIATRIS
VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities. | Viatris Inc. is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. | Booth 1650 – Yupelri (COPD) Booth 1765 – Tobi Podhaler (Cystic Fibrosis) Expo 1569 – Tobi Podhaler (Cystic Fibrosis) – Informational Sessions VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions, and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities. | VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
TidalSense
TidalSense is a series A venture-backed respiratory technology company founded in 2013 and headquartered in Cambridge UK. With a mission to revolutionise population-level outcomes for respiratory patients through pathway transformation, we passionately believe in sustainable innovation designed around the needs of health systems and patients. Our technologies are built on the foundation of our novel patented sensor technology, embedded within the N-Tidal® Handset, which provides unprecedented insight into lung physiology through high accuracy and rapid sampling of CO2. This, combined with the TidalSense cloud platform and AI technologies, drives TidalSense’s diagnostic and monitoring medical device solutions. N-Tidal® Diagnose, is the first new modality (non-spirometry) AI diagnostic device to be cleared under EU Medical Device Regulations for the diagnosis of COPD, setting a new standard and challenging the status quo. It performs near-real-time geometric analysis of breath waveforms to generate a diagnosis at the point of care within a few minutes. Active research areas include adult and paediatric asthma diagnosis and detection of small airways disease. | TidalSense’s N-Tidal® Diagnose is the first non-spirometry CE-marked Class 2a medical device for COPD diagnosis under EU MDR. It combines a patented, fast-response CO2 sensor embedded in the N-Tidal® Handset, with AI algorithms that sensitively detect changes to lung physiology consistent with COPD. This rapid, easy to use device has the potential to replace spirometry in respiratory pathways, offering an easy to use, quick and high accuracy diagnostic alternative for obstructive disease.